Our Biosensor Detection Platform is powered by a biomolecular analyzer, SENEDIA, and semiconductor-based biosensors. We develop the platform based on the core-technology of SiNW-FET that integrates biosensing technologies. Detection results come out real-time upon changes in electrical signals caused by the interaction between bio-probes modified on biosensors and targets in samples, which is fundamentally different from optical-based diagnostics techniques. The limit of detection of this technology is up to 10 to the power of -15 M for nucleic acids and 10 to the power of -12 g/ml for proteins respectively, which facilitates accurate detection for diseases at their early stages. Another advantage of semiconductor biosensor is a single biosensor can be modified with multiple targets, including nucleic acids, antigens, antibodies, bacteria, viruses, environmental chemicals, and etc. With the 1 sample for 1 run setup, our technology enables an easy-to-use and time-saving detection procedure in different environments for various demands as a companions diagnostics and POCT, reaching the goal of personal precise diagnoses.
To cure Acute Myeloid Leukemia, the key reference point of decision making in clinical use is whether malignant cells are eliminated by chemotherapy or not. Thus, the detection of Acute Myeloid Leukemia (AML) has become the indispensable indicator of the therapeutic efficacy.
Q-PCR is the commonly used technology to detect the particular genetic sequence variation of Acute Myeloid Leukemia. The detection limit of Q-PCR is 10 to the power of -5 M as opposed to our biosensor's limit up to 10 to the power of -15 M, meaning our biosensor is capable of detecting residual pathogens to identify patients likely to relapse for doctors to customize treatments to increase patients' survival rates.